Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001140361-23-039411
Filing Date
2023-08-14
Accepted
2023-08-14 07:51:24
Documents
58
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q brhc20056990_10q.htm   iXBRL 10-Q 1062658
2 EXHIBIT 31.1 brhc20056990_ex31-1.htm EX-31.1 12043
3 EXHIBIT 31.2 brhc20056990_ex31-2.htm EX-31.2 11228
4 EXHIBIT 32.1 brhc20056990_ex32-1.htm EX-32.1 5676
5 EXHIBIT 32.2 brhc20056990_ex32-2.htm EX-32.2 5698
  Complete submission text file 0001140361-23-039411.txt   5404739

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA galt-20230630.xsd EX-101.SCH 39055
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE galt-20230630_cal.xml EX-101.CAL 32998
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE galt-20230630_def.xml EX-101.DEF 210218
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE galt-20230630_lab.xml EX-101.LAB 541471
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE galt-20230630_pre.xml EX-101.PRE 340902
52 EXTRACTED XBRL INSTANCE DOCUMENT brhc20056990_10q_htm.xml XML 747545
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

EIN.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-31791 | Film No.: 231166346
SIC: 2834 Pharmaceutical Preparations